NasdaqGS - Delayed Quote USD

Neumora Therapeutics, Inc. (NMRA)

8.96 -0.23 (-2.50%)
At close: May 13 at 4:00 PM EDT
8.99 +0.03 (+0.33%)
After hours: May 13 at 7:30 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Paul L. Berns Co-Founder & Executive Chairman 1.65M -- 1967
Mr. Henry O. Gosebruch President, CEO & Director 3.33M -- 1973
Mr. Jason G. Duncan Chief Legal Officer 315k -- 1974
Mr. Robert Lenz M.D., Ph.D. Head of Research & Development 770.29k -- 1971
Ms. Carol Suh Co-Founder & COO -- -- 1990
Dr. Robert Michael Poole FACP, M.D. Co-Founder & Advisor -- -- 1958
Dr. Joshua Pinto Ph.D. Chief Financial Officer 876.64k -- 1985
Mr. Michael Lee Milligan Principal Accounting Officer -- -- --
Dr. Rajesh Manchanda Ph.D. Chief Technical Operations Officer -- -- 1966
Mr. Nicholas Brandon Ph.D. Chief Scientific Officer -- -- 1974

Neumora Therapeutics, Inc.

490 Arsenal Way
Suite 200
Watertown, MA 02472
United States
857 760 0900 https://www.neumoratx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
120

Description

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Neumora Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

CRGX CARGO Therapeutics, Inc.
19.51
+2.20%
 
LXEO Lexeo Therapeutics, Inc.
13.56
+3.20%
 
MLYS Mineralys Therapeutics, Inc.
12.93
-4.36%
 
KYMR Kymera Therapeutics, Inc.
38.36
+1.21%
 
SLRN Acelyrin, Inc.
4.6900
+0.21%
 
DNLI Denali Therapeutics Inc.
19.30
+5.41%
 
VIGL Vigil Neuroscience, Inc.
3.6500
+14.78%
 
FDMT 4D Molecular Therapeutics, Inc.
25.57
-0.51%
 
ALXO ALX Oncology Holdings Inc.
15.61
-3.70%
 
BOLD Boundless Bio, Inc.
9.52
+10.83%